Journal of the American Heart Association,
Journal Year:
2024,
Volume and Issue:
13(9)
Published: April 19, 2024
Cellular
therapies
have
been
investigated
to
improve
blood
flow
and
prevent
amputation
in
peripheral
artery
disease
with
limited
efficacy
clinical
trials.
Alginate-encapsulated
mesenchymal
stromal
cells
(eMSCs)
demonstrated
improved
retention
survival
promoted
vascular
generation
murine
hind
limb
ischemia
through
their
secretome,
but
large
animal
evaluation
is
necessary
for
human
applicability.
We
sought
determine
the
of
eMSCs
disease-induced
assessment
our
durable
swine
model.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(23), P. 16920 - 16920
Published: Nov. 29, 2023
Mesenchymal
stem
cells
(MSCs)
have
attracted
a
great
deal
of
interest
as
therapeutic
tool
for
renal
fibrosis.
Although
both
adipose-derived
and
bone
marrow-derived
MSCs
(ADSCs
BMSCs,
respectively)
suppress
fibrosis,
which
these
two
has
stronger
effect
remains
unclear.
This
study
aimed
to
compare
the
antifibrotic
effects
ADSCs
BMSCs
extracted
from
adipose
tissue
marrow
derived
same
rats.
When
cultured
in
serum-containing
medium,
had
more
potent
inhibitory
than
on
fibrosis
induced
by
ischemia-reperfusion
injury
serum-free
medium
were
equally
effective
suppressing
Mice
infused
with
(serum-containing
or
cultivation)
higher
death
rate
pulmonary
embolism
those
BMSCs.
In
vitro,
mRNA
levels
factor,
tumor
necrosis
factor-α-induced
protein
6
prostaglandin
E
synthase
while
that
vascular
endothelial
growth
factor
was
ADSCs.
effect,
findings
support
consideration
thromboembolism
risk
clinical
applications.
Our
results
emphasize
importance
deciding
between
based
upon
target
disease
culture
method.
Medical Archives,
Journal Year:
2023,
Volume and Issue:
77(2), P. 90 - 90
Published: Jan. 1, 2023
Background:
Lower
limb
peripheral
artery
disease
(PAD)
is
the
main
risk
of
diabetes
mellitus
which
result
to
high
mortality
rate.
Approximately,
50%
patients
who
receive
several
treatments
have
passed
away
or
lost
limbs
at
a
year’s
follow-up.
Secretome
hypoxia
mesenchymal
stem
cells
(S-MSCs)
contains
active
soluble
molecules
from
MSCs
(H-MSCs)
that
capable
inducing
anti-inflammatory
and
vascular
regeneration
in
PAD.
Objective:
In
this
study,
we
investigated
therapeutic
potential
S-MSCs
improving
dynamic
function
angiogenesis
PAD
diabetic
rats.
Methods:
The
was
established
by
incision
groin
inner
thigh
distal
ligation
femoral
arteries
rats
with
diabetes.
Rats
were
administered
200
µL
400
successfully
filtrated
using
tangential
flow
filtration
(TFF)
system
based
on
various
molecular
weight
cut-off
categories
intravenously.
ELISA
assay
used
analyze
cytokines
growth
factors
contained
S-MSCs.
Tarlov
score
examined
day
1,
3,
5,
7,
10
14.
sacrificed
14
muscle
tissues
collected
for
immunohistochemistry
(IHC)
gene
expression
analysis.
Results:
showed
provides
abundant
level
VEGF,
PDGF,
bFGF,
IL-10
TGFβ.
vivo
administration
remarkably
enhanced
score.
improved
through
enhancing
VEGF
significantly
increasing
CD31
positive
area
tissue
Conclusion:
Our
findings
suggest
could
improves
Journal of the American Heart Association,
Journal Year:
2024,
Volume and Issue:
13(9)
Published: April 19, 2024
Cellular
therapies
have
been
investigated
to
improve
blood
flow
and
prevent
amputation
in
peripheral
artery
disease
with
limited
efficacy
clinical
trials.
Alginate-encapsulated
mesenchymal
stromal
cells
(eMSCs)
demonstrated
improved
retention
survival
promoted
vascular
generation
murine
hind
limb
ischemia
through
their
secretome,
but
large
animal
evaluation
is
necessary
for
human
applicability.
We
sought
determine
the
of
eMSCs
disease-induced
assessment
our
durable
swine
model.
